univers coverag
calendar event
medacorp puls call provid adopt telehealth edt
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
kla confer highlight growth connect valu
bottom line recent attend second annual digit health symposium
utah industri move toward connect care platform offic nation
coordin onc focus improv interoper vendor met appear
driven toward evolv platform effici streamlin solut support patient
engag bi-direct data feed attend event met brent lang ceo
vocera mp spoke sever execut use mp allscript
mp product also heard medic director walgreen mp
respect vocera like manag team product ceo lang sound comfort
firm current sale pipelin activ good growth uk extens
platform seem gain traction expect feedback good still
worri lack backlog growth seemingli high y/i organ growth expect
feedback mix still seem signific challeng
ambulatori revenu cycl product client loyalti high seem win share
allscript believ strategi make sens one spoke indic
physician move touchwork score sunris paragon patient
account seem indic signific room improv lastli walgreen seem
commit engag patient low-cost environ leverag digit solut
grow busi appear challeng
walgreen continu aggress patient engag
solid confer especi year
bottom line rais pt line apo nr takeout price announc
merger affili rcch maintain estim post earn view
expir wait period aug merger like close next month
lpnt report ebitda beat due suppli swb salari wage benefit
expens report small revenu miss driven better-than-expect volum surprisingli
weak price may impact health hospic transfer guidanc
rang narrow around mm adj ebitda midpoint volum trend continu show
improv ss surgeri acceler qoq yoy lpnt price surprisingli weaker
peer flat may impact health hospic transfer margin
expect contract normal due chang integr acquisit class
mm lpnt activ peer ad ambulatori excess point
expect gener due increas capital-expenditure spend new hospit tower
project maintain adj ebitda estim mm mm
view transact rcch like close next month expir
wait period august
recent met rcch ceo martin rash cfo mike browder nashvil aug bu tour
note avail follow link
view apo may seek integr lpnt rcch adopt success rural strategi
latter prepar futur exit strategi
lpnt report ebitda beat due suppli swb expens report small
revenu miss driven better-than-expect volum surprisingli weak price may
impact health hospic transfer
revenu guidanc lower ebitda guidanc rang tighten
chang ebitda estim post
capital-expenditure expect acceler turn posit
rais pt line take price view acquisit
like close next month
outperform market cap price price target methodolog dcf
compar compani analysi ev/sal estim
bottom line yesterday host leerink med-tech leadership seri call ceo
presid dominick colangelo cfo vice-president corpor develop gerard michel daniel
orlando call discuss total address market maci adopt trend
maci epicel strateg plan recent shelf registr manag confid level
sale guidanc key takeaway call acceler biopsi growth
steadi convers rate management signific visibl part
us suggest guidanc impli y/i clearli
achiev like beatabl management estim maci
patient per year translat market opportun lower bullish
estim management also acknowledg estim conserv
grow physician prefer possibl expans barrier
maci adopt physician prefer compani address train
dtc campaign posit real-world outcom major burn center use
epicel patient burn tbsa total bodi surfac area vs approv
label see signific room sale growth exist user increas util
primari focu compani commerci maci epicel management also open
 opportun prompt capit rais june overal call reinforc
view strong adopt momentum maci epicel drive sustain strong double-digit growth
next year given virtual monopoli highli under-penetrated articular cartilag
repair market peg market opportun well actual monopoli sever
burn market peg
md appoint stephen farber new cfo
bottom line md appoint well-season healthcar execut stephen farber evp
cfo succeed vivian lopez-blanco previous announc plan retir
compani view md oper effici realiz pave path
margin expans physician practic effici improv mr farber
year healthcar experi previous cfo knd sale op
juli cfo op also involv privat equiti includ serv executive-
in-resid warburg pincu llc mr farber join md evp expect assum
role cfo novemb md report earn
 methodolog ev ebitda multipl ebitda less nci
 methodolog combin sale dcf analysi wacc lt
ev/sal multipl sale
esmya posit obseva
excel buoy return perform servic growth pt
aug ci sharehold vote esrx merger
ci-esrx deal seen pro-competit manag regulatori risk although
potenti activist activ involv deal see link note
view sharehold vote import binari event expect ci stock trade
vote unsuccess
accord wall street journal carl icahn own less ci stock
plan vote deal link link link
howev remain skeptic sharehold vote deal absent anoth
credibl well-capit buyer ci link link
ci manag indic esrx best capit deploy opportun ci drive
afford better outcom across broad payor mix ci estim
synergi deal success see link ci meet analysi
link analysi link
continu view ci deep valu name patient investor combin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
sourc leerink research compani inform factset price prior day
pdufa teva fremanezumab cgrp migrain
fda adcom neurolog devic panel medic devic
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
chines societi clinic oncolog zlab
european societi retina specialist euretina nite
american colleg clinic pharmacolog
intern associ studi lung cancer
go live az
model model recent updat pleas contact
leerink repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 half full half empti alzheim diseas puls call takeaway market perform
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
deal capac
outperform
outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 vyxeo survey suggest outpati usag grow outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
